EUCTR2022-001315-44-Outside-EU/EEA进行中（未招募）1 期
A Multicenter, Open-label, Pilot Study of TAK-935 (OV935) in Patients With 15Q Duplication Syndrome or CDKL5 DeficiencyDisorder (ARCADE Study) - ARCADE Study
Takeda Development Center America, Inc.0 个研究点开始时间: 2022年5月24日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Clinical diagnosis of Dup 15q or CDKL5 deficiency disorder.
- •2. Currently taking 1 to 6 antiepileptic drugs (AEDs) at a stable dose.
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 20
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 2
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Two or more episodes of convulsive status epilepticus per 3 months requiring
- •hospitalization and intubation.
- •2. Currently receiving a study drug or participated in a clinical study involving another
- •investigational product in the previous month.
研究者
相似试验
未知
1 期
A Phase 1 study of TAK-385 in Patients With Androgen Deprivation Treatment-Naive Prostate CancerJPRN-jRCT2080222485TAKEDA PHARMACEUTICAL COMPANY LTD.43
已完成
1 期
Safety, Tolerability, and Pharmacokinetics of Escalating Single Doses of TAK-935Healthy VolunteersNCT02201056Takeda48
未知
2 期
A Phase 2, Open-label, Single-arm Study of TAK-700 (orteronel) in Patients With Nonmetastatic Castration-resistant Prostate Cancer and Rising Prostate-specific AntigeJPRN-jRCT2080221969Takeda Pharmaceutical Company Limited30
进行中（未招募）
不适用
A Phase I/II multi-center, open label study of TKI258 administered orally on an intermittent schedule in adult patients with advanced or metastatic Renal Cell Cancer (RCC) - N/AEUCTR2007-004391-39-NLovartis Pharma Services AG104
进行中（未招募）
不适用
A Phase I/II multi-center, open label study of TKI258 administered orally on an intermittent schedule in adult patients with advanced or metastatic Renal Cell Cancer (RCC)advanced or metastatic renal cell carcinomaMedDRA version: 9.1Level: LLTClassification code 10050513Term: Metastatic renal cell carcinomaEUCTR2007-004391-39-FRovartis Pharma Services AG81